ATG16L2 as a prognostic biomarker and therapeutic target in kidney renal clear cell carcinoma
Abstract
Kidney renal clear cell carcinoma (KIRC) carries substantial clinical challenges. This study examined ATG16L2, an autophagy-related gene family member, across TCGA, CPTAC, GEO, and an independent cohort to assess its expression patterns, clinicopathological associations, and prognostic relevance. Immune landscapes were characterized through CIBERSORT, ESTIMATE, xCell, and single-cell analyses. Functional investigations employed shRNA-mediated knockdown in KIRC cell lines and xenograft models, with attention to the Notch signaling pathway. ATG16L2 was elevated in KIRC and associated with advanced disease and poorer survival. Its expression correlated with altered immune infiltration and immune checkpoint levels. Silencing ATG16L2 attenuated proliferative, migratory, and invasive capacities, partly through Notch pathway modulation. These findings position ATG16L2 as a prognostic indicator and immune microenvironment modulator in KIRC, with implications for therapeutic strategies targeting the ATG16L2-Notch axis.
Related
- CHCHD2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma: Insights from pan-cancer multi-omics and functional studies
- Disulfidptosis-related genes stratify molecular subtypes and highlight MYH9 as a prognostic biomarker and candidate therapeutic target in pancreatic ductal adenocarcinoma
- Comprehensive Pan-Cancer Bioinformatics Analysis Identifies DHX58 as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Tumor Types
- Multi-omics analysis of GBP2 as a prognostic and immune-associated biomarker in papillary thyroid carcinoma
- Pan-cancer analysis identifies ANGPT4 as a potential prognostic biomarker associated with the tumor microenvironment in kidney renal clear cell carcinoma
BibTeX
@article{xu2026atg16l2,
title = {{ATG16L2 as a prognostic biomarker and therapeutic target in kidney renal clear cell carcinoma}},
author = {Xiaoqun Xu and Chaofeng Zhou and Rui Zhang and Congcong Fan and Qinquan Wang},
journal = {iScience},
year = {2026},
month = oct,
doi = {10.1016/j.isci.2026.117899},
url = {https://www.cell.com/iscience/fulltext/S2589-0042(26)03282-7},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - ATG16L2 as a prognostic biomarker and therapeutic target in kidney renal clear cell carcinoma
AU - Xiaoqun Xu
AU - Chaofeng Zhou
AU - Rui Zhang
AU - Congcong Fan
AU - Qinquan Wang
PY - 2026
DA - 2026/10/14
JO - iScience
DO - 10.1016/j.isci.2026.117899
UR - https://www.cell.com/iscience/fulltext/S2589-0042(26)03282-7
AB - Kidney renal clear cell carcinoma (KIRC) carries substantial clinical challenges. This study examined ATG16L2, an autophagy-related gene family member, across TCGA, CPTAC, GEO, and an independent cohort to assess its expression patterns, clinicopathological associations, and prognostic relevance. Immune landscapes were characterized through CIBERSORT, ESTIMATE, xCell, and single-cell analyses. Functional investigations employed shRNA-mediated knockdown in KIRC cell lines and xenograft models, with attention to the Notch signaling pathway. ATG16L2 was elevated in KIRC and associated with advanced disease and poorer survival. Its expression correlated with altered immune infiltration and immune checkpoint levels. Silencing ATG16L2 attenuated proliferative, migratory, and invasive capacities, partly through Notch pathway modulation. These findings position ATG16L2 as a prognostic indicator and immune microenvironment modulator in KIRC, with implications for therapeutic strategies targeting the ATG16L2-Notch axis.
SN - 2589-0042
ER -